Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 178A (TMEM178A) is a membrane-associated protein encoded by the TMEM178A gene on chromosome 2. It acts as a negative regulator of osteoclast differentiation both in basal and inflammatory conditions, by modulating Ca(2+) fluxes induced by TNFSF11 (RANKL), and thus impacts activation of NFATC1, a key transcription factor in osteoclastogenesis. TMEM178A is localized predominantly to the endoplasmic reticulum membrane. There is some predicted involvement in the regulation of cytosolic calcium ion concentration, suggesting a broader modulatory role in intracellular signaling. While associated with bone metabolism and potentially with hereditary angioedema, it is not currently recognized as a therapeutic target or biomarker in clinical oncology, immunology, or metabolic disease
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 178A (TMEM178A).